Source 1primary paper2025MED
Toolkit/inducible protease variants for GSDME control
inducible protease variants for GSDME control
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
By engineering inducible protease variants whose activity is tightly regulated by an orally bioavailable, clinically approved small molecule, we achieved precise temporal control of pyroptosis.
Usefulness & Problems
Why this is useful
These engineered protease variants provide the inducible cleavage activity that activates the rewired GSDME module. Their activity is controlled by a small molecule to time pyroptosis induction.; small-molecule control of protease activity; temporal gating of pyroptosis
Source:
These engineered protease variants provide the inducible cleavage activity that activates the rewired GSDME module. Their activity is controlled by a small molecule to time pyroptosis induction.
Source:
small-molecule control of protease activity
Source:
temporal gating of pyroptosis
Problem solved
They create a controllable trigger for pyroptosis rather than relying on constitutive or endogenous activation.; provides an external control layer over GSDME cleavage
Source:
They create a controllable trigger for pyroptosis rather than relying on constitutive or endogenous activation.
Source:
provides an external control layer over GSDME cleavage
Problem links
provides an external control layer over GSDME cleavage
LiteratureThey create a controllable trigger for pyroptosis rather than relying on constitutive or endogenous activation.
Source:
They create a controllable trigger for pyroptosis rather than relying on constitutive or endogenous activation.
Published Workflows
Objective: Engineer and functionally validate a chemically inducible GSDME-based gene circuit for precise, externally controlled tumor-cell killing in colorectal cancer models.
Why it works: The workflow rewires GSDME so activation depends on an engineered protease recognition sequence, then couples that trigger to inducible protease variants controlled by an approved small molecule, allowing external timing of pyroptosis before testing antitumor effects in organoids and xenografts.
GSDME cleavagepore formationpyroptotic cell lysisprotease-site rewiringsmall-molecule inducible protease engineeringorganoid validationxenograft validation
Stages
- 1.Design of rewired inducible pyroptosis circuit(library_design)
This stage creates a GSDME effector that can be activated on demand by an engineered, drug-regulated protease rather than by its native proteolytic trigger.
Selection: Replace the native GSDME activation motif with a customized protease recognition sequence and pair it with inducible protease variants regulated by a small molecule.
- 2.Organoid functional characterization(functional_characterization)
This stage tests whether the engineered control logic produces the intended pyroptotic mechanism in a disease-relevant ex vivo model before in vivo testing.
Selection: Assess whether inducer administration produces rapid GSDME cleavage, pore formation, and cell lysis in patient-derived organoids.
- 3.Xenograft confirmatory validation(in_vivo_validation)
This stage evaluates whether externally controlled pyroptosis can translate into tumor growth inhibition in vivo using oral drug administration.
Selection: Test whether oral treatment with the approved drug suppresses tumor growth in a xenograft model.
Steps
- 1.Replace native GSDME activation motif with a customized protease recognition sequenceengineered effector construct
Rewire GSDME so its activation can be controlled by a chosen protease input.
The effector must first be made responsive to an orthogonal protease before small-molecule control can be imposed through inducible protease variants.
- 2.Engineer small-molecule-regulated inducible protease variantscontrol module
Create a drug-gated trigger that activates the rewired GSDME construct on demand.
After rewiring the GSDME cleavage site, a matching inducible protease is needed to provide external temporal control using the approved small molecule.
- 3.Administer inducer in patient-derived organoid models and assess pyroptosis outputsengineered system under test
Determine whether the inducible circuit produces the intended mechanistic outputs of pyroptosis in a disease-relevant model.
Organoid testing provides functional evidence of GSDME cleavage, pore formation, and cell lysis before moving to in vivo tumor studies.
- 4.Treat xenograft-bearing animals orally with the approved drug and measure tumor growth responseengineered system under in vivo validation
Test whether oral drug induction of the circuit yields tumor suppression in vivo.
In vivo validation follows organoid mechanistic success to determine whether the externally controlled pyroptosis strategy translates into tumor growth inhibition.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
Photocleavageprotease-mediated cleavage of rewired gsdmepyroptotic pore formationsmall-molecule-inducible proteolysisTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuatorswitch architecture: cleavage
They require expression of the engineered protease components and administration of the clinically approved small-molecule inducer.; requires the corresponding small-molecule inducer; requires compatibility with the engineered GSDME cleavage sequence
The abstract does not establish the exact dynamic range, leakiness, or portability of the protease variants across other systems.; specific protease architecture and variant names are not supported by the abstract alone
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
In patient-derived organoid models, inducer administration caused rapid GSDME cleavage, pore formation, and robust cell lysis.
In patient-derived organoid models, administration of the inducer led to rapid GSDME cleavage, pore formation, and robust cell lysis.
Engineering inducible protease variants regulated by an orally bioavailable, clinically approved small molecule enabled precise temporal control of pyroptosis.
By engineering inducible protease variants whose activity is tightly regulated by an orally bioavailable, clinically approved small molecule, we achieved precise temporal control of pyroptosis.
In a xenograft model, oral treatment with the approved drug led to marked tumor growth inhibition.
In a xenograft model, oral treatment with the approved drug led to marked tumor growth inhibition.
The platform rewires GSDME activation by replacing its native proteolytic activation motif with a customized protease recognition sequence.
We substituted its native proteolytic activation motif with a customized protease recognition sequence.
The paper reports a chemically inducible gene circuit that uses GSDME to trigger pyroptotic cell death on demand.
Here, we report the design and functional validation of a chemically inducible gene circuit that harnesses Gasdermin E (GSDME) to trigger pyroptotic cell death on demand.
The strategy uses the safety and pharmacokinetics of an approved drug to enable programmable cell death for targeted elimination of treatment-resistant tumors.
This strategy utilizes the safety and pharmacokinetics of an approved drug to enable programmable cell death, providing a versatile platform for the targeted elimination of treatment-resistant tumors.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug inducible-protease-variants-for-gsdme-control
By engineering inducible protease variants whose activity is tightly regulated by an orally bioavailable, clinically approved small molecule, we achieved precise temporal control of pyroptosis.
Source:
application resultsupports
In patient-derived organoid models, inducer administration caused rapid GSDME cleavage, pore formation, and robust cell lysis.
In patient-derived organoid models, administration of the inducer led to rapid GSDME cleavage, pore formation, and robust cell lysis.
Source:
control mechanismsupports
Engineering inducible protease variants regulated by an orally bioavailable, clinically approved small molecule enabled precise temporal control of pyroptosis.
By engineering inducible protease variants whose activity is tightly regulated by an orally bioavailable, clinically approved small molecule, we achieved precise temporal control of pyroptosis.
Source:
Comparisons
Source-stated alternatives
The source frames these variants as an alternative to less controllable gene-based therapeutic strategies, but does not name a specific competing inducible protease system in the abstract.
Source:
The source frames these variants as an alternative to less controllable gene-based therapeutic strategies, but does not name a specific competing inducible protease system in the abstract.
Source-backed strengths
tightly regulated by an orally bioavailable, clinically approved small molecule
Source:
tightly regulated by an orally bioavailable, clinically approved small molecule
Compared with NP-cIPTG
inducible protease variants for GSDME control and NP-cIPTG address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: photocleavage
Relative tradeoffs: appears more independently replicated.
Compared with Opto-Casp8-V1
inducible protease variants for GSDME control and Opto-Casp8-V1 address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: photocleavage
Strengths here: looks easier to implement in practice.
Compared with three-stranded DNAzyme probe
inducible protease variants for GSDME control and three-stranded DNAzyme probe address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: photocleavage
Ranked Citations
- 1.